IN THE CLAIMS

1. (Original) A steroid derivative selected from the group of compounds defined by formula (I) or (II) as shown below, wherein the only difference between said formulas is the bond between carbon number 5 and carbon number 6:



(I)



(II)

wherein

R_1O is in the β-position and R_1 is a hydrogen atom; an NO_2, an SO_3H, an OP(OH)3 an acyl group, or any other group that forms an ester with an inorganic or organic acid; a protecting group, such as CH_3, CH_2OMe, or CH_2O-alkyl; an aliphatic chain which is straight or branched, saturated or unsaturated, or cyclic, including mixed cyclic and aliphatic substituents, which substituents are saturated or unsaturated, aromatic or heterocyclic and contains up to 20 carbon atoms, which substituents can be chosen from hydroxyl, any halogen, amino or alkylamino, carboxylic acid or carboxylic acid ester;

R_2 is R'O in β -position of carbon number 7 or can be (is) hydrogen in the case of

formula (II);
wherein R' independently of R_1, R_3 or R_4 can be any one of the groups defined above in relation to R_1;
R_3 is in α-position and is a hydroxyl group, an acyl-group or an alkoxy group R''O, where R'' independently of R_1, R_3, or R_4 can be any of the groups defined above in relation to R_1;
R_4 is in β-position and is hydrogen, an alkyl group, an acyl group, or an alkoxy group of the formula R'''O, wherein R''' can be any group mentioned for R_1, independent of R_1, R_2, or R_3, for use as a medicament.

2. (Original) A steroid derivative according to claim 1, wherein R_1, R', and/or R'' form one or more ether(s) and/or ester(s) with the steroid.

3. (Previously Presented) A steroid derivative according to claim 1, wherein R_4 is an acyl group, in which hydrogen, or an alkoxy or alkyl group, is attached to the keto group.

4. (Previously Presented) A steroid derivative according to claim 1, wherein R_4 is acetyl (CH_3CO), wherein a keto group is attached to a methyl, which keto-carbon numbered 20 can have any alkyl, alkenyl, alkynyl, aryl, including branched side chains or mixed aromatic and aliphatic side chains, including cyclic saturated hydrocarbons as well as heterocyclic rings or heteroaliphatic chains containing e.g. N, P, O, Si, S, Se, CN, halogens and containing up to 20 carbons.

5. (Previously Presented) A steroid derivative according to claim 1, wherein said steroid is selected from the group consisting of 5-androstene-3β,7β,17α-triol, 5-androstene-3β,17α-diol-7-one, androstane-3β,7β,17α-triol and androstane-3β,17α-diol-7-one, or an ester or ether thereof.

6. (Original) A steroid derivative selected from the group of compounds defined by formula (I) or (II) as shown above, wherein all substituents except R_2 are as defined in claim 1, and R_2 is in the α-position and can be R'O, O= or S=, for use in the

manufacture of a medicament for the treatment and/or prevention of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect.

7-27 (Cancelled)

28. (Currently Amended) Use according to claim [~~7~~] 6, wherein said steroid is selected from the group consisting of 17-hydroxy-pregnenolone (17α-OH), -5-androstene-3β,17α-diol, [~~5-androstene-3β,7β,17α-triol, 5-androstane-3β,7β,17α-triol, 5-androstene-3β,17α-diol-7-one, 5-androstene-3β,7α,17α-triol, 5-androstane-3β,7α,17α-triol, 5-androstane-3β,17α-diol~~], and used for the manufacture of a medicament for non-tumour indications such as conditions dominated by pathologic neovascularisation, such as diabetic retinopathy, exsudative forms of macular degeneration, corneal neovascularisation, and other conditions characterized by neovascularisation, or excessive growth of fibroblasts, such as in hypertropic scars, keloids.